© Springer International Publishing AG 2017Jeffrey Y.C. Wong, Timothy E. Schultheiss and Eric H. Radany (eds.)Advances in Radiation OncologyCancer Treatment and Research10.1007/978-3-319-53235-6_11 The Mammalian DNA Damage Response as a Target for Therapeutic Gain in Radiation…
© Springer International Publishing AG 2017Jeffrey Y.C. Wong, Timothy E. Schultheiss and Eric H. Radany (eds.)Advances in Radiation OncologyCancer Treatment and Research10.1007/978-3-319-53235-6_10 Biomarkers and Radiotherapy Savita V. Dandapani1 (1) Department of Radiation Oncology, City of Hope, Duarte,…
Publication Year Number of patients Median follow-up (months) RT dose Metastases control Overall survival University of Chicago (Wong et al. 2016) 2016 61 82 24–48 Gy in 3 fractions 44% at…
. where P(D, 1) is the probability of a lesion occurring if the entire organ is irradiated to dose D. This formula was derived using the simple notion that the…
Fig. 1 Ideally, drug combinations should shift the balance between the pro-immunogenic and immunosuppressive effects of radiotherapy to favor its pro-immunogenic effects and or abrogate the immune-suppressive ones. Multiple strategies in…
Fig. 1.1 Site of hematopoiesis during fetal development. Hematopoietic stem cells (HSCs) are thought to derive from the ventral mesoderm. The initial blood production termed as “primitive hematopoiesis” occurs in…
Disease Defective gene Protein Inheritance Protein function FHL syndromes without hypopigmentation FHL2 PRF1 Perforin AR Pore formation FHL3 UNC13D Munc13-4 AR Vesicle priming FHL4 STX11 Syntaxin11 AR Vesicle fusion FHL5…
Fig. 4.1 Distribution of patients with myelodysplastic syndrome, myeloproliferative neoplasms, and bone marrow failure in Japan (Reference [3]). One thousand patients were prospectively underwent the central review of morphology and…
Study group Trial Years ALL subtypes No. of patients Age EFS, % (year) OS, % (year) Reference AIEOP/BFM AIEOP-BFM ALL 2000 2000–2006 B-ALL 4016 1–18 80.4 (7) 91.8 (7) Conter…
Disease Clinical characteristic Histologic features CD1a CD14 CD68 CD163 CD207 S100 Factor XIIIa Fascin HLA-DR Others Langerhans cell histiocytosis See text + − +/− − + + − − +…
